SYGNIS Pharma AG has been granted the European and US patent for a new basic technology for the detection of protein-protein interactions, a screening platform for the development of novel drugs.
In the words of SYGNIS’ CEO, Pilar de la Huerta, “the technology will be licensed to a distribution partner and we expect to see our first revenues during the current financial year 2013.”
Protein-protein interactions falls within the scope of proteomics, a field that is growing in importance for research into new customized drugs.
SYGNIS’ new platform can be used to improve the characterization of new drugs in development and identification of new therapeutic targets.
SYGNIS’ technology will increase the potential for generating better drugs within the customized drug development field. Following its merger with the Spanish company X-Pol, which forms part of the GENETRIX Group, SYGNIS aims to become a key player in the growing market for molecular tools and personalized medicine.
SYGNIS aims to use these patents, together with its recent company restructuring and successful implementation of the polymerase QualiPhi™, to enhance the impetus it announced on its merger with X-Pol and become a prominent player in the growing market for new DNA tools and customized drugs, a sector that has seen a two-digit growth rate over the last few years.
According to sources from SYGNIS, this transformation will enable it to obtain its first revenues in 2013 and operating profit in successive years.